版本:
中国

BRIEF-Oragenics - expects to file an investigational new drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017

Nov 21 Oragenics Inc :

* Oragenics - expects to file an investigational new drug (ind) update and initiate a phase 2 study with ag013 in united states and europe in early 2017

* Oragenics -a phase 1b clinical trial with ag013 in 25 head,neck cancer patients at high risk for om demonstrated that ag013 was safe and well tolerated

* U.S. FDA grants fast track designation for the development of oragenics' ag013 for oral mucositis Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐